Enfortumab vedotin prolongs survival in previously treated advanced urothelial carcinoma
1. Enfortumab vedotin showed improved overall survival when compared to chemotherapy in patients with previously treated advanced urothelial carcinoma. 2. ...
1. Enfortumab vedotin showed improved overall survival when compared to chemotherapy in patients with previously treated advanced urothelial carcinoma. 2. ...
Check out the original article from the Lancet Haematology here.
Image: PD 1. Adding angiogenesis-targeted sunitinib therapy to prednisone in the treatment of metastatic castration-resistant prostate cancer (mCRPC) does significantly ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.